A first-in-human, Phase I Study to Evaluate the Safety of TTX-080, an HLA-G Antagonist, in Subjects with Advanced Solid Tumors
G
Greg Durm, MD
Primary Investigator
Enrolling By Invitation
18-100 years
All
Phase
1
2 Locations
Brief description of study
To assess the safety and tolerability of TTX-080
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: tumor
-
Age: Between 18 Years - 100 Years
-
Gender: All
Updated on
01 Aug 2024.
Study ID: 12189
Please visit our main page to search for other studies you may be interested in.
If you need help finding a study or have any questions, please contact us at inhealth@iu.edu
